Last reviewed · How we verify
fenoterol/ipratropium bromide
Fenoterol is a beta-2 agonist that relaxes airway smooth muscle, while ipratropium bromide is an anticholinergic that blocks acetylcholine-mediated bronchoconstriction, together providing dual bronchodilation.
Fenoterol is a beta-2 agonist that relaxes airway smooth muscle, while ipratropium bromide is an anticholinergic that blocks acetylcholine-mediated bronchoconstriction, together providing dual bronchodilation. Used for Chronic obstructive pulmonary disease (COPD), Asthma (maintenance and acute bronchospasm).
At a glance
| Generic name | fenoterol/ipratropium bromide |
|---|---|
| Sponsor | Novartis |
| Drug class | Beta-2 agonist / Anticholinergic combination bronchodilator |
| Target | Beta-2 adrenergic receptor (fenoterol); Muscarinic acetylcholine receptors (ipratropium bromide) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Fenoterol stimulates beta-2 adrenergic receptors on airway smooth muscle, causing relaxation and bronchodilation through increased intracellular cAMP. Ipratropium bromide competitively blocks muscarinic acetylcholine receptors, preventing parasympathetic-mediated airway constriction. The combination provides complementary mechanisms for rapid and sustained airway opening in obstructive airway diseases.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma (maintenance and acute bronchospasm)
Common side effects
- Tremor
- Headache
- Palpitations
- Dry mouth
- Nervousness
- Tachycardia
Key clinical trials
- Functional Strength Training and Neuromuscular Electrical Stimulation in Severe Acute Exacerbations of COPD (NA)
- Continuous Versus Intermittent Nebulization Therapy in Acute Asthma Exacerbation at Emergency Department (NA)
- Prehospital Non-invasive Ventilation for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (NA)
- Bronchodilators on the Exercise Capacity of Bronchiectasis Patients (NA)
- Aerosol Therapy in Obese COPD Patients. (NA)
- Effect of Home-base Exercise With Conical-PEP Device on Physical Performance and Quality of Life in COPD (NA)
- Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease
- Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fenoterol/ipratropium bromide CI brief — competitive landscape report
- fenoterol/ipratropium bromide updates RSS · CI watch RSS
- Novartis portfolio CI